







an Open Access Journal by MDPI

Recent Advances in Pancreatic Surgery for Pancreatic Ductal Adenocarcinoma

Guest Editor:

Dr. Shuji Isaji

1. Professor Emeritus,
Department of Hepato-BiliaryPancreatic and Transplant
Surgery, Mie University, Tsu 5140102, Mie, Japan
2. Advisor, Matsusaka City
Hospital, Matsusaka-shi 5158544, Mie, Japan

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editor

Dear Colleagues,

With recent advances in neoadjuvant and adjuvant treatment modalities for pancreatic ductal carcinoma (PDAC), the outcomes of pancreatic surgery have improved. Additionally, there has been notable progress in surgical techniques after neoadjuvant therapy, such as the aggressive combined resection of major vessels, arterial divestment and the introduction of laparoscopic or robotic surgery.

The focus of this Special Issue is to consider the following research aspects of PDAC (original or review article): (a) resectability classification, (b) PDAC management according to the resectability classification, (c) the indication of conversion surgery and its outcome, (d) novel surgical techniques used for the combined resection of portal veins and major arteries, and (e) the indication of laparoscopic and robotic surgeries.

Dr. Shuji Isaji Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us